Myriad Genetics Announces Reorganization Of European Operations And Sale Of EndoPredict Business; No Financial Terms Disclosed, Deal Is Subject To Customary Closing Conditions, Expects The Transaction To Close In Q2 Or Q3 Of 2024.
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities